|
1
|
Brizal DM and Esclamado R: Concurrent
chemoradiotherapy for locally advanced, nonmetastatic, squamous
carcinoma of the head and neck: Consensus, controversy and
conundrum. J Clin Oncol. 24:2612–2617. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Adelstein DJ, Li Y, Adams GL, Wagner H Jr,
Kish JA, Ensley DF, Schuller DE and Forastiere AA: An intergroup
phase III comparison of standard radiation therapy and two
schedules of concurrent chemothardiotherapy in patients with
unresectable squamous cell head and neck cancer. J Clin Oncol.
21:92–98. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Al-Sarraf M, LeBlanc M, Giri PG, Fu KK,
Cooper J, Vuong T, Forastiere AA, Adams G, Sakr WA, Schuller DE and
Ensley JF: Chemoradiotherapy versus radiotherapy in patients with
advanced nasopharyngeal cancer: Phase III Randomized Intergroup
Study 0099. J Clin Oncol. 16:1310–1317. 1998.PubMed/NCBI
|
|
4
|
Forastiere AA, Goepfert H, Maor M, Pajak
TF, Weber R, Morrison W, Glisson B, Trotti A, Ridge JA, Chao C, et
al: Concurrent chemotherapy and radiotherapy for organ preservation
in advanced laryngeal cancer. N Engl J Med. 349:2091–2098. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Bonner JA, Harari PM, Giralt J, Azarnia N,
Shin DM, Cohen RB, Jones CU, Sur R, Raben D, Jassem J, et al:
Radiotherapy plus cetuximab for squamous-cell carcinoma of the head
and neck. N Engl J Med. 354:567–578. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Eisenhauer EA, Therasse P, Bogaerts J,
Schwartz LH, Sargent D, Ford R, et al: New response evaluation
criteria in solid tumours: Revised RECIST guideline (version 1.1).
Eur J Cancer. 45:226–247. 2009. View Article : Google Scholar
|
|
7
|
Zenda S, Onozawa Y, Tahara M, Kawashima M,
Shikama N, Sasaki S and Boku N: Feasibility study of single agent
cisplatin and concurrent radiotherapy in japanese patients with
squamous cell carcinoma of the head and neck: Preliminary results.
Jpn J Clin Oncol. 37:725–729. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Forastiere AA, Zhang Q, Weber RS, Maor MH,
Goepfert H, Pajak TF, Morrison W, Glisson B, Trotti A, Ridge JA, et
al: Long-term results of RTOG 91-11: A comparison of three
nonsurgical treatment strategies to preserve the larynx in patients
with locally advanced larynx cancer. J Clin Oncol. 31:845–852.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Nguyen-Tan PF, Zhang Q, Ang KK, Weber RS,
Rosenthal DI, Soulieres D, Kim H, Silverman C, Raben A, Galloway
TJ, et al: Randomized phase III trial to test accelerated versus
standard fractionation in combination with concurrent cisplatin for
head and neck carcinomas in the radiation therapy oncology group
0129 trial: Long-term report of efficacy and toxicity. J Clin
Oncol. 32:3858–3866. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Ang KK: Concurrent radiation chemotherapy
for locally advanced head and neck carcinoma: Are we addressing
burning subjects? J Clin Oncol. 22:4657–4659. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Loong HH, Ma BB, Leung SF, Mo F, Hui EP,
Kam MK, Chan SL, Yu BK and Chan AT: Prognostic significance of the
total dose of cisplatin administered during concurrent
chemoradiotherapy in patients with locoregionally advanced
nasopharyngeal carcinoma. Radiother Oncol. 104:300–304. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Ghi MG, Paccagnella A, Floriani I and
Garavaglia D: Concomitant chemoradiation in locally advanced head
and neck squamous cell carcinoma: A literature-based meta-analysis
on the platinum concomitant chemotherapy. J Clin Oncol. 29(Suppl):
55342011.
|
|
13
|
Ang KK, Zhang QE, Rosenthal DI, Nguyen-Tan
P, Sherman EJ, Weber RS, Galvin JM, Bonner JA, Harris J, El-Naggar
AK, et al: Randomized phase III trial of concurrent accelerated
radiation plus cisplatin with or without cetuximab for stage iii to
iv head and neck carcinomas: RTOG 0522. J Clin Oncol. 32:2940–2950.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Koutcher L, Sherman E, Fury M, Wolden S,
Zhang Z, Mo Q, Stewart L, Schupak K, Gelblum D, Wong R, et al:
Concurrent cisplatin and radiation versus cetuximab and radiation
for locally advanced head-and-neck cancer. Int J Radiat Oncol Biol
Phys. 81:915–922. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Ley J, Mehan P, Wildes TM, Thorstad W, Gay
HA, Michel L, Nussenbaum B, Trinkaus K and Adkins D: Cisplatin
versus cetuximab given concurrently with definitive radiation
therapy for locally advanced head and neck squamous cell carcinoma.
Oncology. 85:290–296. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Lefebvre JL, Pointreau Y, Rolland F,
Alfonsi M, Baudoux A, Sire C, de Raucourt D, Malard O, Degardin M,
Tuchais C, et al: Induction chemotherapy followed by either
chemoradiotherapy or bioradiotherapy for larynx preservation: The
TREMPLIN randomized phase II study. J Clin Oncol. 31:853–859. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Ghi MG, Paccagnella A, Ferrari D, Foa P,
Rocca MC, Verri E, Maiello E, Azzaello G, D'Ambrosio C, Casanova C,
et al: A phase II–III study comparing concomitant chemoradiotherapy
(CRT) versus cetuximab/RT (CET/RT) with or without induction
docetaxel/cisplatin/5-fluorouracil (TPF) in locally advanced head
and neck squamous cell carcinoma (LASCCHN): Efficacy results
(NCT0186826). J Clin Oncol. 31(suppl): abstr. 60032013.
|
|
18
|
Meyer F, Fortin A, Wang CS, Liu G and
Bairati I: Predictors of severe acute and late toxicities in
patients with localized head-and-neck cancer treated with radiation
therapy. Int J Radiat Oncol Biol Phys. 82:1454–1462. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Bhaskaran K, Douglas I, Forbes H,
dos-Santos-Silvia I, Leon DA and Smeeth L: Body-mass index and risk
of 22 specific cancers: A population-based cohort study of 5.24
million UK adults. Lancet. 384:755–765. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Sparano JA, Wang M, Zhao F, Stearns V,
Martion S, Ligibel JA, Perez EA, Saphner T, Wolff AC, Sledge GW, et
al: Obesity at diagnosis is associated with inferior outcomes in
hormone receptor-positive operable breast cancer. Cancer.
118:5937–5946. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Weiss L, Melchard T, Habringer S,
Boekstegers A, Hufnagl C, Neureiter D, Hopfinger G, Greil R and
Egle A: Increased body mass index is associated with improved
overall survival in diffuse large B-cell lymphoma. Ann Oncol.
25:171–176. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Dahlberg SE, Schiller JH, Bonomi PB,
Sanler AB, Brahmer JR, Ramalingam SS and Johnson DH: Body mass
index and its association with clinical outcomes for advanced
non-small-cell lung cancer patients enrolled on Eastern cooperative
oncology group clinical trials. J Thorac Oncol. 8:1121–1127. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Arthur AE, Peterson KE, Rozek LS, Tayloe
JM, Light E, Chepeha DB, Hébert JR, Terrell JE, Wolf GT and Duffy
SA: UM Head and Neck SPORE Program: Pretreatment dietary patterns,
weight status and head and neck squamous cell carcinoma prognosis.
Am J Clin Nutr. 97:360–368. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
McRackan TR, Watkins JM, Herrin AE,
Garrett-Mayer EM, Sharma AK, Day TA and Gillespie MB: Effect of
body mass index on chemoradiation outcomes in head and neck cancer.
Laryngoscope. 118:1180–1185. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Takenaka Y, Takemoto N, Nakahara S,
Yamamoto Y, Yasui T, Hanamoto A, Fukusumi T, Michiba T, Cho H,
Yamamoto M and Inohara H: Prognostic significance of body mass
index before treatment of head and neck cancer. Head and Neck.
37:1518–1523. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Chen SW, Yang SN, Liang JA and Lin FJ: The
outcome and prognostic factors in patients with aspiration
pneumonia during concurrent chemoradiotherapy for head and neck
cancer. Eur J Cancer Care (Engl). 19:631–635. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Hunter KU, Lee OE, Lyden TH, Haxer MJ,
Feng FY, Schipper M, Worden F, Prince ME, McLean SA, Wolf GT, et
al: Aspiration pneumonia after chemo-intensity-modulated radiation
therapy of oropharyngeal carcinoma and its clinical and
dysphagia-related predictors. Head and Neck. 36:120–125. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Mortensen HR, Jensen K and Grau C:
Aspiration pneuonia in patients treated with radiotherapy for head
and neck cancer. Acta Oncologica. 52:270–276. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Ottosson S, Lindblom U, Wahlberg P,
Nilsson P, Kjellén E, Zackrisson B, Levring Jäghagen E and Laurell
G: Weight loss and body mass index in relation to aspiration in
patients treated for head and neck cancer: A long-term follow-up.
Support Care Cancer. 22:2361–2369. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Ang KK, Harris J, Wheeler R, Weber R,
Rosenthal DI, Nguyen-Tân PF, Westra WH, Chung CH, Jordan RC, Lu C,
et al: Human papillomavirus and survival of patients with
oropharyngeal cancer. N Engl J Med. 363:24–35. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Posner MR, Lorch JH, Goloubeva O, Tan M,
Schumaker LM, Sarlis NJ, Haddad RI and Cullen KJ: Survival and
human papillomavirus in oropharynx cancer in TAS 324: A subset
analysis from an international phase III trial. Ann Oncol.
22:1071–1077. 2011. View Article : Google Scholar : PubMed/NCBI
|
